Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia

ACHONDROPLASIA, the most common cause of chondrodysplasia in man (1 in 15,000 live births), is a condition of unknown origin characterized by short-limbed dwarfism and macrocephaly1,2. More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals, suggesting that de novo mutations are of paternal origin. Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (l0%))3–6. In contrast, homozygous achondroplasia is usually lethal in the neonatal period and affects 25% of the offspring of matings between heterozygous achondroplasia parents. The gene responsible for achondroplasia has been mapped to chromosome 4pl6.3 (refs 7, 8); the genetic interval encompassing the disease gene contains a member of the fibroblast-growth-factor receptor (FGFR3) family which is expressed in articular chondrocytes. Here we report the finding of recurrent missense mutations in a CpG doublet of the transmembrane domain of the FGFR3 protein (glycine substituted with arginine at residue 380, G380R) in 17 sporadic cases and 6 unrelated familial forms of achondroplasia. We show that the mutant genotype segregates with the disease in these families. Thus it appears that recurrent mutations of a single amino acid in the transmembrane domain of the FGFR3 protein account for all cases (23/23) of achondroplasia in our series.

[1]  D. Housman,et al.  A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. , 1991, Genomics.

[2]  M. Hayman,et al.  Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Maroteaux,et al.  Homozygous achondroplasia: morphologic and biochemical study of cartilage. , 1990, American journal of medical genetics.

[4]  E. Castilla,et al.  The birth prevalence rates for the skeletal dysplasias. , 1986, Journal of medical genetics.

[5]  K. Nakashima,et al.  Reduction of basic fibroblasts growth factor receptor is coupled with terminal differentiation of chondrocytes. , 1991, The Journal of biological chemistry.

[6]  L. Williams Signal transduction by the platelet-derived growth factor receptor. , 1989, Science.

[7]  J. Gusella,et al.  The gene for achondroplasia maps to the telomeric region of chromosome 4p , 1994, Nature Genetics.

[8]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[9]  B. Ponder,et al.  Mutations of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.

[10]  E. Pasquale A distinctive family of embryonic protein-tyrosine kinase receptors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Iwamoto,et al.  Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation. , 1990, The Journal of biological chemistry.

[12]  R. Gardner A new estimate of the achondroplasia mutation rate , 1977, Clinical genetics.

[13]  C. Stoll,et al.  Birth prevalence rates of skeletal dysplasias , 1989, Clinical genetics.

[14]  Jean Weissenbach,et al.  A gene for achondroplasia–hypochondroplasia maps to chromosome 4p , 1994, Nature Genetics.

[15]  K. K. Smith,et al.  Achondroplasia—a genetic and statistical survey , 1970, Annals of human genetics.

[16]  D. Danks,et al.  Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. , 1979, Journal of medical genetics.

[17]  P. Leder,et al.  Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. , 1992, The Journal of biological chemistry.